Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

Drugs

Every IDH-mutant glioma program in this file, grouped by class. Open a drug for its studies and the sources behind each figure.

ClassNone selected
Route

A route is listed here when at least one program uses it. The full list is on Methods. Unknown means the source did not name a route.

All programs shown

15 of 15 programs shown

alkylating chemotherapy 2 drugs

ATR inhibitor (ATRX-altered) 1 drug

  • TuvusertibGEINOPhase 2Route n/r1 studyATR inhibitor (ATRX-altered)

DNMT inhibitor 1 drug

mutant IDH1 inhibitor 3 drugs

mutant IDH1/IDH2 inhibitor 2 drugs

PARP inhibitor 3 drugs

  • NiraparibMassachusetts General HospitalPhase 1oral1 studyPARP inhibitor
  • OlaparibHospices Civils de Lyon (OLAGLI)Phase 2oral3 studiesPARP inhibitor
  • Pamiparib + TemozolomideUniversity of California, San FranciscoPhase 1oral1 studyPARP inhibitor

PD-1 antibody 1 drug

  • NivolumabNational Cancer InstitutePhase 2intravenous1 studyPD-1 antibody

peptide vaccine 1 drug

retinoid plus PD-1 antibody 1 drug

  • Tretinoin (ATRA) + RetifanlimabUniversity of Pennsylvania (Stephen Bagley)Phase 2tretinoin, oral. retifanlimab, intravenous1 studyretinoid plus PD-1 antibody